11.94
+1.44%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Jiangsu Aidea Pharmaceutical Group Co
Its shares trade on Shanghai under the ticker 688488.SS. It has been listed since 20 July 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥720.7m and a net loss of CN¥19.7m. At that date it held total assets of CN¥1.91bn and shareholders' equity of CN¥964.7m.
Jiangsu Aidea Pharmaceutical Co., Ltd. engages in the production, supply, research and development of UTI raw materials. The company is headquartered in Yangzhou, Jiangsu. The company went IPO on 2020-07-20. The firm is also engaged in the development and sales of some generic drugs, human immunodeficiency virus (HIV) diagnostic equipment and reagents. The firm is also engaged in the research and development of innovative drugs in anti-Acquired Immune Deficiency Syndrome (AIDS), anti-inflammatory and anti-tumor drugs fields. The firm's human-source protein products mainly include crude ulinastatin, crude urekline, crude urokinase and intermediates of ulinastatin. The firm mainly distributes its products within domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Jul 2020
- Employees
- 421
- Website
- aidea.com.cn ↗
Leadership
Pay as last reported
- Mr. Heliang FuChairman of the Board, since 2014CN¥709,100
- Mr. Jie ZhangPresident, Chief Executive Officer, Director, since 2023
- Ms. Chuanhong ZhuChief Financial Officer
- Mr. Gaohong GuSenior Vice President
- Ms. Guangrong WangVice President, Director, since 2015CN¥735,300
- Mr. Hong QinVice President, Chief Medical Officer
- Mr. Rong DaQuality SupervisorCN¥388,200
- Mr. Wenquan LiResearch and Development Technical DirectorCN¥593,400
- Mr. Gufang SuDeputy Director of Active Pharmaceutical Ingredient ProductionCN¥320,900
- Mr. Yu YuanDirector of Biological Research and DevelopmentCN¥760,800
- Mr. Jibing ZhangFactory Manager (Human Protein)CN¥656,000
- Ms. Yan LiuSecretary of the Board, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Jiangsu Aidea Pharmaceutical Group employs 421 full-time employees for biotechnology research and development.
- The company produces UTI raw materials and human-source protein products like ulinastatin and urokinase.
- Jiangsu Aidea focuses on innovative drug development in anti-AIDS, anti-inflammatory, and anti-tumor fields.
Weaknesses
- The company's products are distributed solely within the domestic market of China.
- Jiangsu Aidea's business relies on generic drugs and HIV diagnostic equipment sales.
- The firm's research and development is limited to specific therapeutic areas without global expansion.
Opportunities
- Expanding into international markets could leverage Jiangsu Aidea's biotechnology expertise.
- Growing demand for HIV diagnostic equipment presents a market opportunity in China.
- Increasing focus on anti-tumor drug development aligns with global health trends.
Threats
- Domestic market dependency increases vulnerability to local economic fluctuations.
- Competition in the Chinese biotechnology sector may intensify with new entrants.
- Regulatory changes in China's health care industry could impact product approvals.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.